June 25, 2001Archives of Internal Medicine
Low-Molecular-Weight Heparins in the Treatment of Acute Coronary Syndromes
Why the study?
Do low-molecular-weight heparins reduce coronary events compared to unfractionated heparin in patients with acute coronary syndromes?
Population
Patients with acute coronary syndromes, specifically non-ST segment elevation acute coronary ischemia
Comparison
Low-molecular-weight heparins vs Unfractionated heparin
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports enoxaparin preference in NSTE-ACS; leaves open class effects among other LMWHs.
Structured PICO
Do low-molecular-weight heparins reduce coronary events compared to unfractionated heparin in patients with acute coronary syndromes?
P
Population
Patients with acute coronary syndromes, specifically non-ST segment elevation acute coronary ischemia
I
Intervention
Low-molecular-weight heparins (specifically enoxaparin sodium)
C
Comparator
Unfractionated heparin
O
Outcome
Coronary events (death or myocardial infarction)hard clinical
Low-molecular-weight heparins, particularly enoxaparin, offer practical advantages and clinical efficacy over unfractionated heparin in managing non-ST segment elevation acute coronary syndromes.
Cite This Study
Turpie et al. (2001) studied this question.